Core Viewpoint - The article highlights the significant advancements in the treatment of relapsed/refractory multiple myeloma through BCMA-targeted ADC therapies, particularly the promising results from the global DREAMM-7 study, which showcases the efficacy of the drug Mabeparatuzumab in improving patient outcomes [1][4][6]. Group 1: ADC Market and Innovations - The ADC sector has become a leading area for innovation in China, with over 22 related transactions last year totaling more than $20 billion [1]. - ADCs have demonstrated efficacy across various tumor types, including breast, gastric, and lung cancers, and are now making strides in treating multiple myeloma [1][2]. - The emergence of BCMA-targeted ADCs represents a new hope for patients with relapsed/refractory multiple myeloma, as highlighted by recent clinical findings [2][3]. Group 2: Clinical Study Results - The DREAMM-7 study included 494 patients and compared the efficacy of Mabeparatuzumab with the classic CD38 monoclonal antibody Daratumumab, revealing significant survival advantages for the Mabeparatuzumab group [4][5]. - In the Chinese subgroup of the DREAMM-7 study, the median progression-free survival (mPFS) for the Mabeparatuzumab group was not reached, while the Daratumumab group had an mPFS of 8.4 months [5]. - The complete response rate for the Mabeparatuzumab group was 50%, significantly higher than the 22.5% in the Daratumumab group, indicating a strong therapeutic potential [5][6]. Group 3: Safety and Regulatory Recognition - The safety profile of the BCMA ADC therapy in the Chinese subgroup was consistent with global findings, showing manageable safety [6]. - The National Medical Products Administration of China has granted breakthrough therapy designation to Mabeparatuzumab, indicating its potential as a significant treatment option for multiple myeloma patients [6][7]. - The results from the Chinese study reflect a shift in clinical research from a follower to a leader role, showcasing China's capabilities in developing breakthrough therapies [7].
中国研究闪耀EHA,BCMA-ADC突破多发性骨髓瘤复发困局
Jiang Nan Shi Bao·2025-06-17 09:19